S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.98 (-1.53%)
MSFT   413.61 (+-0.01%)
META   499.46 (+1.90%)
GOOGL   137.90 (-0.40%)
AMZN   177.89 (+0.64%)
TSLA   202.58 (+0.35%)
NVDA   817.50 (+3.33%)
NIO   5.83 (+1.39%)
AMD   200.59 (+4.19%)
BABA   74.75 (+0.97%)
T   17.00 (+0.41%)
F   12.48 (+0.32%)
MU   95.34 (+5.22%)
CGC   3.26 (-0.91%)
GE   159.15 (+1.44%)
DIS   111.89 (+0.28%)
AMC   4.47 (+3.47%)
PFE   26.63 (+0.26%)
PYPL   60.49 (+0.25%)
XOM   105.99 (+1.41%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.98 (-1.53%)
MSFT   413.61 (+-0.01%)
META   499.46 (+1.90%)
GOOGL   137.90 (-0.40%)
AMZN   177.89 (+0.64%)
TSLA   202.58 (+0.35%)
NVDA   817.50 (+3.33%)
NIO   5.83 (+1.39%)
AMD   200.59 (+4.19%)
BABA   74.75 (+0.97%)
T   17.00 (+0.41%)
F   12.48 (+0.32%)
MU   95.34 (+5.22%)
CGC   3.26 (-0.91%)
GE   159.15 (+1.44%)
DIS   111.89 (+0.28%)
AMC   4.47 (+3.47%)
PFE   26.63 (+0.26%)
PYPL   60.49 (+0.25%)
XOM   105.99 (+1.41%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.98 (-1.53%)
MSFT   413.61 (+-0.01%)
META   499.46 (+1.90%)
GOOGL   137.90 (-0.40%)
AMZN   177.89 (+0.64%)
TSLA   202.58 (+0.35%)
NVDA   817.50 (+3.33%)
NIO   5.83 (+1.39%)
AMD   200.59 (+4.19%)
BABA   74.75 (+0.97%)
T   17.00 (+0.41%)
F   12.48 (+0.32%)
MU   95.34 (+5.22%)
CGC   3.26 (-0.91%)
GE   159.15 (+1.44%)
DIS   111.89 (+0.28%)
AMC   4.47 (+3.47%)
PFE   26.63 (+0.26%)
PYPL   60.49 (+0.25%)
XOM   105.99 (+1.41%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.98 (-1.53%)
MSFT   413.61 (+-0.01%)
META   499.46 (+1.90%)
GOOGL   137.90 (-0.40%)
AMZN   177.89 (+0.64%)
TSLA   202.58 (+0.35%)
NVDA   817.50 (+3.33%)
NIO   5.83 (+1.39%)
AMD   200.59 (+4.19%)
BABA   74.75 (+0.97%)
T   17.00 (+0.41%)
F   12.48 (+0.32%)
MU   95.34 (+5.22%)
CGC   3.26 (-0.91%)
GE   159.15 (+1.44%)
DIS   111.89 (+0.28%)
AMC   4.47 (+3.47%)
PFE   26.63 (+0.26%)
PYPL   60.49 (+0.25%)
XOM   105.99 (+1.41%)
NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

$28.23
+1.33 (+4.94%)
(As of 12:27 PM ET)
Today's Range
$27.26
$30.27
50-Day Range
$12.65
$26.90
52-Week Range
$6.40
$30.27
Volume
1.27 million shs
Average Volume
2.49 million shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.50

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
14.6% Upside
$33.50 Price Target
Short Interest
Healthy
19.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Dyne Therapeutics in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$47.30 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.76) to ($3.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.17 out of 5 stars

Medical Sector

552nd out of 957 stocks

Pharmaceutical Preparations Industry

260th out of 440 stocks


DYN stock logo

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
DYN Mar 2024 20.000 call
Dyne Therapeutics: An Updated Analysis
DYN Mar 2024 10.000 call
DYN Mar 2024 20.000 put
DYN Mar 2024 22.500 put
DYN Mar 2024 30.000 call
DYN Mar 2024 25.000 put
Dyne Therapeutics Inc (DYN)
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
3/01/2024
Next Earnings (Estimated)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DYN
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.50
High Stock Price Target
$56.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+24.5%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-168,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.84 per share

Miscellaneous

Free Float
41,195,000
Market Cap
$1.65 billion
Optionable
Optionable
Beta
0.87
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

4 equities research analysts have issued 12-month price targets for Dyne Therapeutics' shares. Their DYN share price targets range from $20.00 to $56.00. On average, they predict the company's share price to reach $33.50 in the next year. This suggests a possible upside of 20.3% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN shares have increased by 109.4% and is now trading at $27.85.
View the best growth stocks for 2024 here
.

Are investors shorting Dyne Therapeutics?

Dyne Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 7,250,000 shares, a drop of 15.2% from the January 31st total of 8,550,000 shares. Based on an average daily trading volume, of 1,800,000 shares, the short-interest ratio is currently 4.0 days. Currently, 19.1% of the shares of the stock are sold short.
View Dyne Therapeutics' Short Interest
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its earnings results on Monday, October, 30th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.16.

What ETF holds Dyne Therapeutics' stock ?

Morningstar US Small Growth holds 9,078 shares of DYN stock, representing 2.59% of its portfolio.

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.80%), Vida Ventures Advisors LLC (3.38%), Franklin Resources Inc. (3.12%), Wasatch Advisors LP (2.74%), Frazier Life Sciences Management L.P. (1.93%) and Goldman Sachs Group Inc. (1.89%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 3/1/2024 by MarketBeat.com Staff